Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 20, 2026, 6:53 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 81 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: FORTEO Clear all
Completed No phase listed Observational Results available

Real-world Effectiveness and Cardiovascular Safety Study of Abaloparatide in Postmenopausal Women

NCT04974723
View directory record Official record
Conditions
Osteoporosis, Postmenopausal
Interventions
Abaloparatide, Teriparatide
Drug
Lead sponsor
Radius Health, Inc.
Industry
Eligibility
50 Years and older · Female only
Enrollment
22,054 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Apr 19, 2024 · Synced Oct 20, 2026, 6:53 PM EDT
Completed Phase 2 Interventional Results available

Effect of Alendronate on Bone in People With Chronic Spinal Cord Injury (SCI) Previously Treated With Teriparatide

NCT02195895
View directory record Official record
Conditions
Spinal Cord Injury, Bone Loss, Osteoporosis
Interventions
Alendronate, Calcium, Vitamin D
Drug · Dietary Supplement
Lead sponsor
Northwestern University
Other
Eligibility
21 Years and older
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Mar 30, 2023 · Synced Oct 20, 2026, 6:53 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Bone Modeling Effects of Combined Anabolic/Antiresorptive Administration

NCT04026256
View directory record Official record
Conditions
Postmenopausal Osteoporosis
Interventions
Teriparatide, Denosumab
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
45 Years and older · Female only
Enrollment
37 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2022
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Aug 2, 2023 · Synced Oct 20, 2026, 6:53 PM EDT
Completed Phase 4 Interventional

Effects of Teriparatide in Postmenopausal Women With Osteoporosis

NCT00079924
View directory record Official record
Conditions
Postmenopausal Osteoporosis
Interventions
teriparatide, aldrenodate, raloxifene
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
50 Years and older · Female only
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2007
U.S. locations
10
States / cities
Birmingham, Alabama • Huntsville, Alabama • Scottsdale, Arizona + 7 more
Source: ClinicalTrials.gov public record
Updated May 25, 2007 · Synced Oct 20, 2026, 6:53 PM EDT
Completed Phase 3 Interventional Results available

Combination Risedronate - Parathyroid Hormone Trial in Male Osteoporosis

NCT01611571
View directory record Official record
Conditions
Osteoporosis
Interventions
Risedronate, Teriparatide, Placebo Teriparatide, placebo Risedronate
Drug
Lead sponsor
Columbia University
Other
Eligibility
30 Years to 85 Years · Male only
Enrollment
31 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2011
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Mar 4, 2014 · Synced Oct 20, 2026, 6:53 PM EDT
Completed Phase 2 Interventional Results available

Denosumab, Teriparatide or Both for the Treatment of Postmenopausal Osteoporosis

NCT00926380
View directory record Official record
Conditions
Osteoporosis
Interventions
denosumab, teriparatide
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
45 Years and older · Female only
Enrollment
94 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2016
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jun 29, 2018 · Synced Oct 20, 2026, 6:53 PM EDT
Completed Phase 2 Interventional Results available

PTH(1-34) and Pelvic Fracture Healing - a Randomized Controlled Trial

NCT02972424
View directory record Official record
Conditions
Osteoporotic Fractures
Interventions
Teriparatide Prefilled Syringe, Placebo
Drug
Lead sponsor
Hospital for Special Surgery, New York
Other
Eligibility
65 Years and older
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2021
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jul 27, 2022 · Synced Oct 20, 2026, 6:53 PM EDT
Completed Phase 4 Interventional

OPTAMISE: Clinical Effectiveness of Teriparatide After Alendronate or Risedronate Therapy in Osteoporotic Postmenopausal Women

NCT00130403
View directory record Official record
Conditions
Osteoporosis, Postmenopausal
Interventions
risedronate sodium
Drug
Lead sponsor
Sanofi
Industry
Eligibility
55 Years to 85 Years · Female only
Enrollment
290 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2007
U.S. locations
1
States / cities
Bridgewater, New Jersey
Source: ClinicalTrials.gov public record
Updated Jan 11, 2011 · Synced Oct 20, 2026, 6:53 PM EDT
Completed Phase 4 Interventional Results available

Effects of Teriparatide or Zoledronic Acid Treatment on Bone in Postmenopausal Osteoporotic Women

NCT00927186
View directory record Official record
Conditions
Osteoporosis, Post-menopausal
Interventions
Teriparatide, Zoledronic Acid
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
55 Years to 89 Years · Female only
Enrollment
69 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2012
U.S. locations
9
States / cities
Lakewood, Colorado • Atlanta, Georgia • Gainesville, Georgia + 6 more
Source: ClinicalTrials.gov public record
Updated Apr 4, 2013 · Synced Oct 20, 2026, 6:53 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Suspected Deficient Activation of Vitamin D in Patients With Secondary Hyperparathyroidism

NCT00754442
View directory record Official record
Conditions
Secondary Hyperparathyroidism
Interventions
Teriparatide
Drug
Lead sponsor
University of Maryland, Baltimore
Other
Eligibility
40 Years to 59 Years · Female only
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2008
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Apr 1, 2022 · Synced Oct 20, 2026, 6:53 PM EDT
Completed Phase 4 Interventional Results available

Novel Combination Therapy for Osteoporosis in Men

NCT03994172
View directory record Official record
Conditions
Male Osteoporosis
Interventions
Teriparatide or human parathyroid hormone (PTH) 1-34, Cinacalcet, placebo tablet, Calcium citrate tablet, Vitamin D3
Drug · Dietary Supplement
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
60 Years to 85 Years · Male only
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2025
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Sep 3, 2026 · Synced Oct 20, 2026, 6:53 PM EDT
Completed Phase 2Phase 3 Interventional Accepts healthy volunteers Results available

Forteo for the Treatment of Unexplained Osteoporosis in Premenopausal Women

NCT00697463
View directory record Official record
Conditions
Menopause, Fracture, Osteoporosis
Interventions
Teriparatide (PTH 1-34)
Drug
Lead sponsor
Columbia University
Other
Eligibility
20 Years to 48 Years · Female only
Enrollment
22 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2012
U.S. locations
2
States / cities
Omaha, Nebraska • New York, New York
Source: ClinicalTrials.gov public record
Updated Jul 26, 2018 · Synced Oct 20, 2026, 6:53 PM EDT
Completed Phase 4 Interventional Results available

Study of Teriparatide (FORTEO) to Treat Adults With Osteogenesis Imperfecta

NCT00131469
View directory record Official record
Conditions
Osteogenesis Imperfecta
Interventions
Teriparatide (FORTEO), Placebos
Drug
Lead sponsor
Oregon Health and Science University
Other
Eligibility
18 Years to 85 Years
Enrollment
79 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2011
U.S. locations
3
States / cities
Baltimore, Maryland • Portland, Oregon • Houston, Texas
Source: ClinicalTrials.gov public record
Updated Apr 24, 2019 · Synced Oct 20, 2026, 6:53 PM EDT
Completed Phase 3 Interventional Results available

Study of the Experience of Patients With Osteoporosis Using the Forteo B Pen to Self Administer Once Daily Teriparatide Therapy

NCT00577863
View directory record Official record
Conditions
Osteoporosis
Interventions
teriparatide
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
Not listed
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008
U.S. locations
18
States / cities
Huntsville, Alabama • Montgomery, Alabama • Peoria, Arizona + 15 more
Source: ClinicalTrials.gov public record
Updated Jul 22, 2009 · Synced Oct 20, 2026, 6:53 PM EDT
Completed Not applicable Interventional Results available

Renal Osteodystrophy: An Individual Management Approach

NCT02440581
View directory record Official record
Conditions
Kidney Failure, Chronic
Interventions
Alendronate, Teriparatide, Cinacalcet
Drug
Lead sponsor
Hartmut Malluche, MD
Other
Eligibility
21 Years and older
Enrollment
141 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2021
U.S. locations
1
States / cities
Lexington, Kentucky
Source: ClinicalTrials.gov public record
Updated Jan 5, 2023 · Synced Oct 20, 2026, 6:53 PM EDT
Completed Phase 4 Interventional Results available

Effect of Parathyroid Hormone (PTH) and Weight-Bearing on Bone in Spinal Cord Injury (SCI)

NCT00826228
View directory record Official record
Conditions
Osteoporosis, Bone Loss, Spinal Cord Injury
Interventions
teriparatide, weight-bearing
Drug · Other
Lead sponsor
Thomas J. Schnitzer
Other
Eligibility
18 Years to 75 Years
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2012
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Jul 11, 2013 · Synced Oct 20, 2026, 6:53 PM EDT
Completed Phase 3 Interventional Results available

Effect of Teriparatide on Hip Fracture Healing

NCT01473589
View directory record Official record
Conditions
Femur Neck Fracture
Interventions
Teriparatide, Placebo, Calcium supplementation, Vitamin D supplementation
Drug · Dietary Supplement
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
50 Years and older
Enrollment
122 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
24
States / cities
Phoenix, Arizona • Tucson, Arizona • La Mesa, California + 21 more
Source: ClinicalTrials.gov public record
Updated Apr 16, 2015 · Synced Oct 20, 2026, 6:53 PM EDT
Active, not recruiting Phase 4 Interventional

Novel Precision Medicine Approach to Treatment of Osteoporosis Based on Bone Turnover

NCT05151484
View directory record Official record
Conditions
Age-Related Osteoporosis
Interventions
Teriparatide, Alendronate
Drug
Lead sponsor
Madhumathi Rao
Other
Eligibility
40 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
1
States / cities
Lexington, Kentucky
Source: ClinicalTrials.gov public record
Updated May 14, 2026 · Synced Oct 20, 2026, 6:53 PM EDT
Completed Phase 4 Interventional Results available

A Study That Will Compare the Effect of Two Drugs on Participants With Low Bone Mass and a Recent Hip Fracture

NCT00887354
View directory record Official record
Conditions
Osteoporosis
Interventions
Teriparatide, Risedronate, Placebo, Calcium, Vitamin D
Drug · Dietary Supplement
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
50 Years and older
Enrollment
224 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2015
U.S. locations
6
States / cities
Fort Lauderdale, Florida • New Port Richey, Florida • Orlando, Florida + 3 more
Source: ClinicalTrials.gov public record
Updated Sep 25, 2019 · Synced Oct 20, 2026, 6:53 PM EDT
Terminated Phase 2 Interventional Results available

A Phase II Study Evaluating SB-751689 in Post-Menopausal Women With Osteoporosis.

NCT00471237
View directory record Official record
Conditions
Osteoporosis
Interventions
Ronacaleret, Teriparatide, Alendronate
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years to 79 Years · Female only
Enrollment
564 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
9
States / cities
Oakland, California • Palm Desert, California • Walnut Creek, California + 6 more
Source: ClinicalTrials.gov public record
Updated Nov 7, 2017 · Synced Oct 20, 2026, 6:53 PM EDT
Terminated Phase 2 Interventional Accepts healthy volunteers Results available

The Impact of Parathyroid Hormone (PTH) on Craniofacial Osseous Regeneration in Bone

NCT01279187
View directory record Official record
Conditions
Implant
Interventions
Teriparatide, Placebo
Drug
Lead sponsor
University of Michigan
Other
Eligibility
30 Years to 85 Years
Enrollment
27 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2015
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Feb 7, 2018 · Synced Oct 20, 2026, 6:53 PM EDT
Completed Phase 3 Interventional

Once Weekly Parathyroid Hormone for Osteoporosis

NCT00065637
View directory record Official record
Conditions
Osteopenia, Osteoporosis
Interventions
Teriparatide, Placebo teriparatide
Drug
Lead sponsor
University of California, San Francisco
Other
Eligibility
45 Years to 70 Years · Female only
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2005
U.S. locations
1
States / cities
Bangor, Maine
Source: ClinicalTrials.gov public record
Updated Feb 5, 2013 · Synced Oct 20, 2026, 6:53 PM EDT
Terminated Phase 2 Interventional Results available

Teriparatide for Postsurgical Hypoparathyroidism

NCT01171690
View directory record Official record
Conditions
Hypoparathyroidism Post-surgical
Interventions
Teriparatide
Drug
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years to 80 Years
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2013
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Dec 22, 2014 · Synced Oct 20, 2026, 6:53 PM EDT
Withdrawn No phase listed Observational

Knee Osteoarthritis Outcome Measures in Arthritic Patients With Osteoporosis

NCT03217513
View directory record Official record
Conditions
Osteoporosis, Knee Osteoarthritis
Interventions
Not listed
Lead sponsor
Edward Fox
Other
Eligibility
40 Years to 80 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2024
U.S. locations
1
States / cities
Hershey, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Oct 24, 2019 · Synced Oct 20, 2026, 6:53 PM EDT